CEO James Rosen (Artizan)
Precision inflammation drugs? Yale spinout Artizan clinches $11M and Biohaven deal to single out bad bacteria
As a Yale spinout based in New Haven, Artizan Biosciences was pretty familiar with Biohaven — a successful neuro-focused drug developer and “shining star,” as Artizan CEO James Rosen puts it, in the burgeoning biotech community there.
But when a board director and an investor tried connecting the two, they were in for a surprise.
“Unbeknownst to Artizan, Biohaven had been doing a landscaping exercise surveying microbiome companies with whom to partner for CNS disorders,” Rosen told Endpoints News, “and lo and behold, they found Artizan right in their backyard.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters